Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	323.46	96.69	489.71	230.44	4.16
Short-Term Investments	216.29	318.12	-	-	-
Cash & Short-Term Investments	539.75	414.8	489.71	230.44	4.16
Cash Growth	16.81%	-15.30%	112.51%	5442.09%	-
Other Current Assets	5.16	7.25	12.82	0.63	0.83
Total Current Assets	544.92	422.05	502.53	231.07	4.98
Net Property, Plant & Equipment	1.77	2.03	0.85	0.82	0.64
Other Long-Term Assets	6.91	6.91	6.62	2.09	1.08
Total Assets	553.6	430.99	510	233.98	6.7
Accounts Payable	7.44	7.79	4.51	3.19	5.14
Accrued Expenses	30.76	20.04	12.88	11.61	18.76
Current Portion of Leases	1.14	1.12	0.61	0.29	-
Total Current Liabilities	39.34	28.95	17.99	15.09	23.9
Long-Term Leases	0.3	0.59	0.13	0.37	-
Other Long-Term Liabilities	-	-	-	0.02	0.09
Total Long-Term Liabilities	0.3	0.59	0.13	0.39	0.09
Total Liabilities	39.64	29.54	18.12	15.47	23.98
Common Stock	0.01	0.01	0.01	0	0
Additional Paid-in Capital	929.37	760.17	712.88	4.25	2.23
Accumulated Other Comprehensive Income	-0.24	0.24	-	-	-
Retained Earnings	-415.18	-358.97	-221.02	-153.02	-101.04
Total Common Shareholders' Equity	513.96	401.45	491.88	-148.77	-98.8
Minority Interest	-	-	-	367.28	81.53
Shareholders' Equity	513.96	401.45	491.88	218.51	-17.28
Total Liabilities & Equity	553.6	430.99	510	233.98	6.7
Total Debt	1.44	1.71	0.74	0.66	0
Net Cash (Debt)	538.31	413.09	488.97	229.78	4.16
Net Cash Growth	30.31%	-15.52%	112.80%	5426.29%	-
Net Cash Per Share	9.57	7.55	29.10	396.10	9.69
Book Value	513.96	401.45	491.88	-148.77	-98.8
Book Value Per Share	9.14	7.34	29.27	-256.45	-230.26
Tangible Book Value	513.96	401.45	491.88	-148.77	-98.8
Tangible Book Value Per Share	9.14	7.34	29.27	-256.45	-230.26

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q